About Rani Therapeutics Holdings, Inc.
Rani Therapeutics develops oral biologic delivery via its RaniPill capsule — clinical-stage, micro-cap, negligible revenue. High volatility, no dividend. Thin options liquidity and binary trial risk make CSP selling dangerous; wide bid-ask spreads typical at this market cap.
Biotechnology